Waldenstrom's Macroglobulinemia Research This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

A 74-Year-Old Man With Waldenstr öm Macroglobulinemia and Progressive Dyspnea
Chest. 2024 Feb;165(2):e39-e43. doi: 10.1016/j.chest.2023.08.004.ABSTRACTA 74-year-old man presented to our department with progressive dyspnea on exertion over the last year. The patient did not report any other symptoms. He had previously smoked with a 60 pack-year history. He worked in an office and did not report any environmental, occupational, or domestic exposures. His history included asymptomatic Waldenström's macroglobulinemia that was diagnosed 18 months before respiratory symptoms. He was not receiving any treatment and was monitored regularly by the hematology department.PMID:38336442 | DOI:10.1016/j.chest.20...
Source: Chest - February 9, 2024 Category: Respiratory Medicine Authors: Vasilios Tzilas Andrew G Nicholson Maria Gavriatopoulou Ioannis Ntanasis-Stathopoulos Meletios A Dimopoulos Demosthenes Bouros Source Type: research

Circulating tumor cells in Waldenström macroglobulinemia
Leukemia, Published online: 09 February 2024; doi:10.1038/s41375-024-02156-3Circulating tumor cells in Waldenström macroglobulinemia (Source: Leukemia)
Source: Leukemia - February 9, 2024 Category: Hematology Authors: Cl émentine Boccon-Gibod Elise Sourdeau Pierre Morel Elise Chapiro Florence Nguyen-Khac Clotilde Bravetti Fr édéric Davi V éronique Morel Nicolas Gauthier Adrien Grenier In ès Boussen Sylvain Choquet V éronique Leblond Magali Le Garff-Tavernier Mari Source Type: research

Russell body duodenitis: a rare condition
Rev Esp Enferm Dig. 2024 Feb 2. doi: 10.17235/reed.2024.10270/2024. Online ahead of print.ABSTRACTRussell bodies are accumulations of immunoglobulins within hyperstimulated plasma cells of the intestinal mucosa associated with chronic inflammation of benign progression, but may be confused with lymphoplasmacytic lymphoma, MALT lymphoma, multiple myeloma, or "signet-ring" cells, among others. There are few cases of gastric involvement, but duodenal involvement is even rarer with less than 10 published cases. Endoscopic examination with quality biopsies and anatomopathologic analysis with immunohistochemistry are essential t...
Source: Revista Espanola de Enfermedades Digestivas - February 2, 2024 Category: Gastroenterology Authors: Helena Gonz ález Sánchez Gloria Meijide Santos Cristina Fuente D íaz Olegario Casta ño Fernández Source Type: research

Waldenstr öm Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology
J Natl Compr Canc Netw. 2024 Jan;22(1D):e240001. doi: 10.6004/jnccn.2024.0001.ABSTRACTThe treatment of Waldenström macroglobulinemia/lymphoplasmacytic lymphoma (WM/LPL) has evolved to include several new options. The NCCN Guidelines for WM/LPL provide a framework on which to base decisions regarding diagnosis, treatment, assessment of response to treatment, and follow-up of both newly diagnosed and previously treated WM/LPL.PMID:38244272 | DOI:10.6004/jnccn.2024.0001 (Source: Journal of the National Comprehensive Cancer Network : JNCCN)
Source: Journal of the National Comprehensive Cancer Network : JNCCN - January 20, 2024 Category: Cancer & Oncology Authors: Shaji K Kumar Natalie S Callander Kehinde Adekola Larry D Anderson Muhamed Baljevic Rachid Baz Erica Campagnaro Jorge J Castillo Caitlin Costello Christopher D'Angelo Benjamin Derman Srinivas Devarakonda Noura Elsedawy Alfred Garfall Kelly Godby Jens Hill Source Type: research

Phase I study of the Syk inhibitor sovleplenib in relapsed or refractory mature B-cell tumors
Haematologica. 2024 Jan 18. doi: 10.3324/haematol.2022.282401. Online ahead of print.ABSTRACTSovleplenib (HMPL-523) is a selective spleen tyrosine kinase (Syk) inhibitor with antitumor activity in preclinical models of B-cell malignancy. We conducted a dose-escalation and dose-expansion phase I study of sovleplenib in patients with relapsed/refractory mature Bcell tumors. Dose escalation followed a 3+3 design; patients received oral sovleplenib (200-800 mg once daily [q.d.] or 200 mg twice daily [b.i.d.], 28-day cycles). During dose expansion, patients were enrolled into four cohorts per lymphoma classification and treated...
Source: Haematologica - January 18, 2024 Category: Hematology Authors: Yuqin Song Junning Cao Qingyuan Zhang Caixia Li Lugui Qiu Junyuan Qi Huilai Zhang Wenyu Li Lihong Liu Hongmei Jing Keshu Zhou Weijing Zhang Liling Zhang Daqi Li Liqun Zou Haiyan Yang Wenbin Qian Hui Zhou Jianda Hu Hongyan Yin Sisi Fu Songhua Fan Qian Xu J Source Type: research

Ibrutinib Efficacy, Safety, and Pharmacokinetics in Chinese Patients with Relapsed or Refractory Waldenstr öm's Macroglobulinemia: A Multicenter, Single-Arm, Phase 4 Study
CONCLUSIONS: Ibrutinib demonstrated durable responses in Chinese patients with r/r WM. Treatment was well tolerated with no new safety signals compared with the pivotal global studies. Ibrutinib exposure was also comparable between Chinese and non-Chinese patients.TRIAL REGISTRATION: ClinicalTrials.gov identifier NCT04042376.PMID:38079089 | DOI:10.1007/s12325-023-02720-w (Source: Adv Data)
Source: Adv Data - December 11, 2023 Category: Epidemiology Authors: Shuhua Yi Zhen Cai Yu Hu Aili He Sujun Gao Qian Li Linlin Sha Nating Zhang Yupeng Ren Xue Gai Xue Yang Rui Qin Lugui Qiu Source Type: research

Ibrutinib Efficacy, Safety, and Pharmacokinetics in Chinese Patients with Relapsed or Refractory Waldenstr öm’s Macroglobulinemia: A Multicenter, Single-Arm, Phase 4 Study
ConclusionsIbrutinib demonstrated durable responses in Chinese patients with r/r WM. Treatment was well tolerated with no new safety signals compared with the pivotal global studies. Ibrutinib exposure was also comparable between Chinese and non-Chinese patients.Trial RegistrationClinicalTrials.gov identifier NCT04042376. (Source: Advances in Therapy)
Source: Advances in Therapy - December 11, 2023 Category: Drugs & Pharmacology Source Type: research

Waldenstr öm Macroglobulinemia: Targeted Agents Taking Center Stage
AbstractWith the worldwide approval of the oral covalent Bruton tyrosine kinase (BTK) inhibitors ibrutinib and zanubrutinib for treating patients with Waldenstr öm macroglobulinemia (WM), targeted agents have certainly taken center stage in the therapeutic landscape of WM. This review discusses the biological and clinical data supporting current and up-and-coming targeted agents in WM. Bruton tyrosine kinase inhibitors induce fast, deep, and durable respon ses in patients with WM, comparable to chemoimmunotherapy; however, there is a glaring absence of comparative studies between these regimens. The high response and prog...
Source: Drugs - December 6, 2023 Category: Drugs & Pharmacology Source Type: research

OP15 Analysis of the Multidisciplinary Approach for the Management of Patients Affected by Waldenstrom's Macroglobulinemia, Marginal Zone Lymphoma and Chronic Lymphocytic Leukemia in Italy
The study aims to analyze the importance of the multidisciplinary approach as compared to the current Italian standard of care for the management of patients affected by either WM, MZL or CLL based on the involvement of several health professional figures. (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: E. Di Brino, D. Antonini, G. Falasca, M. Basile, F. Rumi, L. Giorgio, R. Laurita, A. Cicchetti Source Type: research

HSD66 Treatment Pathway and Unmet Needs of Waldenstr öm Macroglobulinemia: An Exploratory Study from Portugal
This study aimed to give a general overview of the treatment pathway and unmet needs of Waldenstr öm Macroglobulinemia (WM) in Portugal. (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: K. Dimitrovova, A. Reis, D.S. Viana Source Type: research

EPH248 Varying Latency Impact on Incidence of Second Primary Malignancy Among Patients with B-Cell Malignancy
The objective was to investigate the incidence rate (IR) of second primary malignancy (SPM) following B-cell malignancy diagnosis (chronic lymphocytic leukemia [CLL], mantle cell [MCL], marginal zone [MZL], Waldenstr öm macroglobulinemia [WM], diffuse large B-cell, follicular, hairy cell leukemia). (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: T. Knight, L. Zhou, R. Patel, S. Azmi Source Type: research